Monoclonal antibody · Agonist of 4-1BB (CD137) (TNFRSF9) · developed by PFIZER
Utomilumab is a human IgG2 monoclonal antibody that binds and activates 4-1BB (CD137, TNFRSF9) on CD8-positive and CD4-positive T cells and natural killer cells. This agonism enhances 4-1BB signaling and cytokine production to promote anti-tumor immune responses. It is studied in advanced malignancies, non-small cell lung cancer, ovarian cancer, urothelial cancer and solid tumors.
Summary written with AI from the sources listed at the end of this page.
Advanced MalignanciesNSCLCOvarian CancerSolid TumorsUrothelial Cancer
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →